Enjoy complimentary customisation on priority with our Enterprise License!
The viral vectors market share is expected to increase by USD 490.64 million from 2021 to 2026, and the market’s growth momentum will accelerate at a CAGR of 14.23%.
The viral vectors market research report provides valuable insights into the post-COVID-19 impact on the market, which will help companies evaluate their business approaches. Furthermore, this report extensively covers viral vectors market segmentation by application (gene therapy and vaccines) and geography (North America, Europe, Asia, and Rest of World (ROW))
The viral vectors market report also offers information on several market vendors, including Batavia Biosciences BV, Bayer AG, Catalent Inc., Creative Biogene, Danaher Corp., F. Hoffmann La Roche Ltd., FinVector Oy, Freeline Therapeutics Holdings plc, FUJIFILM Holdings Corp, Institut Merieux, Lonza Group Ltd., Merck KGaA, Novartis AG, Oxford Biomedica Plc, REGENXBIO Inc, Sirion Biotech GmbH, Takara Holdings Inc, Thermo Fisher Scientific Inc., uniQure NV, and Virovek Inc among others.
Batavia Biosciences BV is a privately held company headquartered in The Netherlands. It is a global company, with limited information regarding its financials and limited information regarding its employee strength is available. Its revenue from the global viral vectors market is a key component of its overall revenues. The company offers a wide range of viral vectors such as adenoviruses and lentiviruses.
Get the Viral Vectors Market Size Forecast by Downloading the Report Sample
Technavio categorizes the global viral vectors market as a part of the global healthcare equipment market. Our research report extensively covers external factors influencing the parent market growth potential in the coming years, which will determine the levels of growth of the viral vectors market during the forecast period.
Based on our research output, there has been a neutral impact on the market growth during and post-COVID-19 era. The rising prevalence of chronic diseases is notably driving the viral vectors market growth, although factors such as challenges associated with the production and manufacturing of viral vectors may impede the market growth. Our researchers analyzed the data with 2022 as the base year, along with the key drivers, trends, and challenges. A holistic analysis of drivers will help companies refine their marketing strategies to gain a competitive advantage.
Key Viral Vectors Market Driver
The rising prevalence of chronic diseases is one of the key drivers supporting the viral vectors market growth. Despite advances in treatment options, the prevalence and incidence of several life-threatening diseases are rising. According to the CDC, in 2020, an estimated 1.1 million adults and adolescents were living with HIV in the US. In 2020, in the US, 30,635 individuals who were diagnosed with HIV died. According to the European Centre for Disease Prevention and Control (ECDC), in 2020, in Europe, 560 000 people in the EU and the European Economic Area (EEA) were diagnosed with HIV. Thus, the rising prevalence and incidence of such diseases have encouraged vendors to develop curative therapies using viral vectors. Hence, the rising prevalence and incidence of such diseases will drive the growth of the market during the forecast period.
Key Viral Vectors Market Trend
The increasing number of R&D activities for the development of gene therapies and vaccines using viral vectors is one of the key viral vectors market trends contributing to the market growth. Primarily, researchers are focusing on the development of gene therapies and vaccines using viral vectors, which will drive the growth of the market during the forecast period. For instance, Lokon Pharma AB is conducting a Phase I/II clinical trial to evaluate LOAd703, together with the standard of care chemotherapy, on patients with cancer, including pancreatic, biliary, colorectal, and ovarian cancer. OAd703 is an immunostimulatory gene therapy that uses a selection replication-competent adenovirus vector. Such an increasing number of R&D activities for the development of gene therapies and vaccines using viral vectors will fuel the growth of the market during the forecast period.
Key Viral Vectors Market Challenge
Challenges associated with the production and manufacturing of viral vectors is one of the factors hindering the viral vectors market growth. Viral vectors have emerged as the preferred vehicle in ongoing gene therapy trials. Recombinant adeno-associated virus-based vectors are the most widely used of all gene therapy products that are in development. They show high potential for delivery in gene therapy indications, such as cancer. However, the development of manufacturing processes for novel viral vectors is time-consuming and expensive. From the perspective of the development of wide gene therapies, current scale-up approaches are not adequate to supply the required number of doses to allow late-stage clinical trials to progress, which hinders the development of gene therapy products. Moreover, during process manipulation, steps can result in damage to viral capsids leading to loss of infectivity and functionality. Such challenges may hinder the production and manufacturing of viral vectors, which will affect the growth of the market during the forecast period.
This viral vectors market analysis report also provides detailed information on other upcoming trends and challenges that will have a far-reaching effect on the market growth. The actionable insights on the trends and challenges will help companies evaluate and develop growth strategies for 2022-2026.
Our In-house experts produce extensive information on the value chain and parent market of the viral vectors market, which vendors can leverage to gain a competitive advantage during the forecast period. The Value Chain information provides an end-to-end understanding of product insight and profit and also optimization and evaluation of business strategies. The players across the value chain include selective data and analysis from entire research findings as per the scope of the report.
Get a glance at the market share of various regions by Requesting a PDF Sample now!
39% of the market’s growth will originate from North America during the forecast period. The US and Canada are the key markets for the viral vectors market in North America. Market growth in this region will be slower than the market growth in Europe and Asia.
The strong prevalence of infectious and non-infectious diseases and the increasing investments in developing gene therapies and vaccines will facilitate the viral vector market growth in North America over the forecast period. This market research report entails detailed information on the competitive intelligence, marketing gaps, and regional opportunities in store for vendors, which will assist in creating efficient business plans.
COVID Impact and Recovery Analysis
The regional market witnessed slow growth, especially in 2020 and 2021, owing to the outbreak of COVID-19. However, viral vector-based COVID-19 vaccines were produced, which positively impacted the market in 2021. Research institutes and healthcare facilities engaged in gene therapy started developing new gene therapy products and treatments for individuals with cancer, which increased the demand for viral vectors. Hence, the increasing focus of research institutes and gene therapy vendors on developing innovative gene therapies is expected to drive the growth of the market during the forecast period.
Request a PDF Sample to gain insights into the market contribution of various segments
The viral vectors market share growth in the gene therapy segment will be significant during the forecast period. Viral vectors are used for the treatment of various disorders, such as hematologic, metabolic, cardiovascular, ophthalmologic, and infectious diseases, as well as diverse types of cancer. The use of viral vectors in gene therapy is a method that has the potential to achieve the direct, targeted, in vivo delivery of genes into the host. The characteristics of a viral vector for gene therapy include its easy purification into high titers to mediate targeted gene delivery and its prolonged gene expression with nominal side effects. Such characteristics of gene therapy will boost the market growth in the coming years.
This report provides an accurate prediction of the contribution of all the segments to the growth of the viral vectors market size and actionable market insights on the post-COVID-19 impact on each segment.
Viral Vectors Market Scope |
|
Report Coverage |
Details |
Page number |
137 |
Base year |
2021 |
Forecast period |
2022-2026 |
Growth momentum & CAGR |
Accelerate at a CAGR of 14.23% |
Market growth 2022-2026 |
$ 490.64 million |
Market structure |
Fragmented |
YoY growth (%) |
12.28 |
Regional analysis |
North America, Europe, Asia, and Rest of World (ROW) |
Performing market contribution |
North America at 39% |
Key consumer countries |
US, Canada, UK, China, and Japan |
Competitive landscape |
Leading companies, Competitive strategies, Consumer engagement scope |
Key companies profiled |
Batavia Biosciences BV, Bayer AG, Catalent Inc., Creative Biogene, Danaher Corp., F. Hoffmann La Roche Ltd., FinVector Oy, Freeline Therapeutics Holdings plc, FUJIFILM Holdings Corp, Institut Merieux, Lonza Group Ltd., Merck KGaA, Novartis AG, Oxford Biomedica Plc, REGENXBIO Inc, Sirion Biotech GmbH, Takara Holdings Inc, Thermo Fisher Scientific Inc., uniQure NV, and Virovek Inc |
Market dynamics |
Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, and Market condition analysis for the forecast period. |
Customization purview |
If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
We can help! Our analysts can customize this report to meet your requirements. Get in touch
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Five Forces Analysis
5 Market Segmentation by Application
6 Customer Landscape
7 Geographic Landscape
8 Drivers, Challenges, and Trends
9 Vendor Landscape
10 Vendor Analysis
11 Appendix
Get lifetime access to our
Technavio Insights
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.